We are live on
!
Find out more
CCM
Camber Capital Management Portfolio holdings
AUM
$1.07B
1-Year Est. Return
8.19%
This Fund
S&P 500
This Quarter
Est. Return
-3.09%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$1.9B
AUM Growth
-$244M
(-11%)
Cap. Flow
-$155M
Cap. Flow
% of AUM
-8.17%
Top 10 Holdings %
Top 10 Hldgs %
53.17%
Holding
39
New
8
Increased
10
Reduced
6
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$81.5M |
| 2 |
Alkermes
ALKS
|
+$72.1M |
| 3 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$50.7M |
| 4 |
NVO
Novo Nordisk
NVO
|
+$35.4M |
| 5 |
AbbVie
ABBV
|
+$34.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$67.6M |
| 2 |
MDCO
Medicines Co
MDCO
|
+$62M |
| 3 |
Teva Pharmaceuticals
TEVA
|
+$60M |
| 4 |
AGN
Allergan plc
AGN
|
+$40.7M |
| 5 |
DaVita
DVA
|
+$29M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 89.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Myriad Genetics
MYGN
$291M
| $28.6M | 1.51% |
+1,000,000
| New | +$29.1M |
|
27
Cyclerion Therapeutics
CYCN
$14.7M
| $27M | 1.42% |
111,353
+33,257
| +43% | +$7.18M |
|
28
GSK
GSK
$103B
| $21.3M | 1.12% |
400,000
| – | – |
|
|
WMGI
29
DELISTED
Wright Medical Group Inc
WMGI
| $15.5M | 0.81% |
+750,000
| New | +$17.9M |
|
|
CBIO
30
Crescent Biopharma
CBIO
$549M
| $15.1M | 0.79% |
+35,000
| New | +$22.5M |
|
|
TBIO
31
DELISTED
Translate Bio, Inc. Common Stock
TBIO
| $14.9M | 0.78% |
+1,500,000
| New | +$14.2M |
|
|
TECX
32
Tectonic Therapeutic
TECX
$524M
| $7.06M | 0.37% |
+41,667
| New | +$9.43M |
|
33
Sutro Biopharma
STRO
$400M
| $5.45M | 0.29% |
60,000
| – | – |
|
34
Surgery Partners
SGRY
$2.07B
| $1.18M | 0.06% |
160,084
| – | – |
|
|
35
Gilead Sciences
GILD
$161B
| – | – |
-1,000,000
| Closed | -$67.6M |
|
36
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$803B
| – | – |
-1,000,000
| Closed | -$293M |
|
|
37
Teva Pharmaceuticals
TEVA
$39.7B
| – | – |
-6,500,000
| Closed | -$60M |
|
38
TG Therapeutics
TGTX
$7.25B
| – | – |
-1,000,000
| Closed | -$8.65M |
|
|
MDCO
39
DELISTED
Medicines Co
MDCO
| – | – |
-1,700,000
| Closed | -$62M |
|
Similar funds
PP
SAF
NRD
FC
GIM
SC
BWA
CCP
Camber Capital Management's Q3 2019 Portfolio in Review
As of Q3 2019, Camber Capital Management held 39 positions worth $1.9B, down 11% from $2.15B the previous quarter. Its ten largest holdings account for 53% of the portfolio.
Camber Capital Management withdrew a net $155M in Q3 2019, closing 5 positions and reducing 6 holdings. Its most notable exit was Gilead Sciences, an estimated $67.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 75% a quarter earlier.
Against the trend, Camber Capital Management opened a new position in Biogen worth $81.5M.
- Camber Capital Management's largest Q3 2019 buy was Biogen: 350,000 shares worth $81.5M.
- Camber Capital Management added most to Alkermes in Q3 2019, an estimated $72.1M increase.
- Camber Capital Management's biggest Q3 2019 reduction was Allergan plc, cutting an estimated $40.7M.
- Camber Capital Management fully exited Gilead Sciences in Q3 2019, selling an estimated $67.6M.
- Camber Capital Management's ten largest holdings make up 53% of its $1.9B portfolio in Q3 2019.
- Camber Capital Management opened 8 new positions and closed 5 in Q3 2019.
- Camber Capital Management's portfolio value fell 11% quarter-over-quarter to $1.9B.
Based on Camber Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.